Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2019 Financial Results on February 6, 2020


Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and full year 2019 financial results on Thursday, February 6, 2020 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Thursday, February 6, 2020
1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

REPLAY access

About Seattle Genetics

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative medicines targeting cancer to make a meaningful difference in people's lives. ADCETRIS® (brentuximab vedotin) and PADCEVTM (enfortumab vedotin-ejfv) use the company's industry-leading antibody-drug conjugate (ADC) technology designed to bring a powerful medicine directly to cancer cells. ADCETRIS is approved for the treatment of several types of CD30-expressing lymphomas, and PADCEV is approved to treat adults with metastatic urothelial cancer. In addition, investigational agent tucatinib, a small molecule tyrosine kinase inhibitor, is in late-stage development for HER2-positive metastatic breast cancer, and in clinical development for metastatic colorectal cancer. The company is headquartered in Bothell, Washington, and has offices in California, Switzerland and the European Union. For more information on our robust pipeline, visit www.seattlegenetics.com and follow @SeattleGenetics on Twitter.


These press releases may also interest you

at 12:55
Ecodrive Awarded $300,000+ in Seed Funding at San Diego Angel Conference VI, with Runner Up Achieve Clinics Securing a $100,000+ Investment
San Diego Angel Conference (SDAC) at the University of San Diego (USD), a program in its sixth year that activates accredited angel investors and engages promising early-stage companies, today awarded two startups with angel funding for their...

at 12:51
Dr. Scott Kamelle Introduces Da Vinci 5: A Quantum Leap in Robotic Surgical Innovation
Dr. Scott Kamelle, a trailblazer in the realm of robotic surgery, begins his work with the highly anticipated Da Vinci 5 robotic surgery system, marking a monumental advancement in surgical precision, efficiency, and patient care. With an array of...

at 12:40
Kooler Garage Doors Celebrates Pascual Ramos as Grand Junction's First Master Technician Certified by IDEA
Kooler Garage Doors, a leader in providing premium garage door services across the Western Slope of...

at 12:35
Ryan Named to the 2024 Best Places to Work in Illinois List for the 13th Year
Ryan, a leading global tax services and software provider, has been named a Best Place to Work in Illinois for the 13th year, receiving first place in the Large Company category. The annual program, presented by the Best Companies Group and published...

at 12:06
ExxonMobil Hit with $725M Verdict for Failure to Warn About Cancer-Causing Benzene in Gasoline
A Philadelphia jury has returned a $725.5 million verdict against ExxonMobil, finding the company's failure to warn about known health risks of exposure to cancer-causing benzene in its petroleum products was responsible for a former service station...

at 12:05
Be Biopharma Announces New Preclinical Data for Novel B Cell Medicine for the Potential Treatment of Hypophosphatasia
Be Biopharma, Inc. ("Be Bio"), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), today presented results from new preclinical research demonstrating production of active ALP by a BCM, which highlights BCMs as a...

More news about Science and technology...


News published on and distributed by: